Cancer, Orphan, Pediatric Drug Developers Join China Foreign Data Acceptance Party
Executive Summary
China officially issues regulation accepting clinical data obtained from overseas studies, with a priority on treatments for critical, rare and pediatric conditions.
You may also be interested in...
Alembic Charts China Plans And Sees Price Cuts As No Dampener
Alembic has firmed up a joint venture to tap into emerging opportunities in China amid evolving regulations there, and believes the market holds significant promise despite rising price pressures.
Alembic Charts China Plans, Sees Price Cuts As No Dampener
Alembic has firmed up a joint venture to tap into emerging opportunities in China amid evolving regulations there, and believes the market holds significant promise despite rising price pressures.
China Beckons: Sun Joins Indian Firms Priming For Larger Presence
Evolving regulations and emerging opportunities appear to have put China firmly on the radar of several frontline Indian firms. Sun Pharma is the latest to join those seeking a larger play in the Asian market.